DexCom, Inc. (NASDAQ:DXCM) Stock Has Consensus Price Target of $89.08 According to Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average recommendation of “Moderate Buy” from the twenty-four analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $89.74.

A number of equities research analysts have weighed in on DXCM shares. UBS Group set a $96.00 target price on DexCom and gave the stock a “buy” rating in a report on Tuesday, July 28th. Raymond James Financial restated a “strong-buy” rating and set a $94.00 price target on shares of DexCom in a report on Friday, July 31st. Citigroup reaffirmed a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Benchmark raised their price objective on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, BTIG Research reiterated a “buy” rating and issued a $90.00 price objective (up from $80.00) on shares of DexCom in a research note on Friday, July 31st.

DexCom Stock Performance

Shares of DexCom stock opened at $86.23 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The business has a 50-day moving average price of $86.43 and a two-hundred day moving average price of $74.47. DexCom has a 1-year low of $54.11 and a 1-year high of $92.59. The company has a market cap of $32.54 billion, a P/E ratio of 34.08, a PEG ratio of 1.45 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period last year, the company posted $0.48 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, analysts anticipate that DexCom will post 2.64 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Jereme Sylvain sold 3,638 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 76,069 shares of company stock valued at $5,872,307 over the last 90 days. Insiders own 0.28% of the company’s stock.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of DexCom in the 4th quarter worth $483,356,000. Legal & General Group Plc acquired a new position in DexCom during the second quarter worth $173,237,000. Deutsche Bank AG acquired a new position in DexCom during the second quarter worth $164,035,000. Employees Provident Fund Board acquired a new position in DexCom during the fourth quarter worth $145,352,000. Finally, J. Stern & Co. LLP lifted its stake in shares of DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after buying an additional 1,529,641 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.